Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc > Financing done at 11.6 cents pre-consolidation numbers

<< Previous

Bullboard Posts

Next >>

Comment by DIYGuyon Sep 28, 2017 5:36pm

134 Views

Post# 26755986

RE:RE:RE:RE:Financing done at 11.6 cents pre-consolidation numbers

I do not see the documents on Sedar. I'll take your word for it. Can't say if those amounts are significant or not without knowing people's personal situations. I would be concerned if they did not participate. I realize they don't have to with the options they receive, but why would anyone put their faith in their discoveries if they don't risk some of their own money as well.

Someone selling over 20,000 shares at $1.15. Still think that is someone selling to buy into the 2nd tranche. Makes sense for an accredited investor. Lose one penny for the right to buy all those shares at $1.21 for a year. 2nd tranche needs to close and then announce dosing of 1st patient in HNSSC trial.

I wonder how many shares Dr Danter still holds?

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland